219 related articles for article (PubMed ID: 34359554)
1. Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities.
Zarrabi K; Walzer E; Zibelman M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359554
[TBL] [Abstract][Full Text] [Related]
2. Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.
Wilson NR; Acikgoz Y; Hasanov E
Int J Cancer; 2024 Mar; 154(6):947-961. PubMed ID: 37823185
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
4. The role of immunotherapy in non-clear cell renal cell carcinoma.
Climent C; Soriano S; Bonfill T; Lopez N; Rodriguez M; Sierra M; Andreu P; Fragio M; Busquets M; Carrasco A; Cano O; Seguí MA; Gallardo E
Front Oncol; 2023; 13():941835. PubMed ID: 36816976
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
[TBL] [Abstract][Full Text] [Related]
6. The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma.
Naik P; Dudipala H; Chen YW; Rose B; Bagrodia A; McKay RR
Ther Adv Urol; 2024; 16():17562872241232578. PubMed ID: 38434237
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database.
Koguchi T; Naito S; Hatakeyama S; Numakura K; Muto Y; Kato R; Kojima T; Kawasaki Y; Morozumi K; Kandori S; Kawamura S; Nishiyama H; Ito A; Habuchi T; Obara W; Ohyama C; Tsuchiya N; Kojima Y
Cancer Med; 2023 Nov; 12(22):20677-20689. PubMed ID: 37905674
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y
Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
Bellmunt J; Dutcher J
Ann Oncol; 2013 Jul; 24(7):1730-1740. PubMed ID: 23625974
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma.
Osterman CK; Rose TL
Kidney Cancer; 2020; 4(1):15-27. PubMed ID: 34435168
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
[TBL] [Abstract][Full Text] [Related]
12. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview.
Bergmann L; Weber S; Hartmann A; Ahrens M
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1273-1286. PubMed ID: 34291700
[No Abstract] [Full Text] [Related]
13. Genomic profiles of renal cell carcinoma in a small Chinese cohort.
Tai S; Xu DD; Yu Z; Guan Y; Yin S; Xiao J; Xue S; Liang C
Front Oncol; 2023; 13():1095775. PubMed ID: 37427096
[TBL] [Abstract][Full Text] [Related]
14. Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience.
Bimbatti D; Pierantoni F; Lai E; Ballestrin M; Cavasin N; Erbetta E; De Toni C; Basso U; Maruzzo M
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686629
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.
Barata P; Gulati S; Elliott A; Hammers HJ; Burgess EF; Gartrell BA; Darabi S; Bilen MA; Basu A; Geynisman DM; Dawson NA; Zibelman MR; Zhang T; Wei S; Ryan CJ; Heath EI; Poorman KA; Nabhan C; McKay RR
J Clin Invest; 2024 Apr; 134(11):. PubMed ID: 38652565
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma.
Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T
Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410
[TBL] [Abstract][Full Text] [Related]
17. Characterizing Tumor Thrombus Arising from Non-Clear Cell Renal Cell Carcinoma.
Rabinowitz MJ; Esfandiary T; Cheaib J; Patel SH; Alam R; Metcalf M; Enikeev D; Pierorazio PM; Ged YMA; Allaf ME; Singla N
Eur Urol Open Sci; 2022 Sep; 43():28-34. PubMed ID: 36353070
[TBL] [Abstract][Full Text] [Related]
18. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature.
John A; Spain L; Hamid AA
Curr Oncol; 2023 Jan; 30(1):923-937. PubMed ID: 36661719
[TBL] [Abstract][Full Text] [Related]
19. Contemporary Drug Therapy for Renal Cell Carcinoma- Evidence Accumulation and Histological Implications in Treatment Strategy.
Yamana K; Ohashi R; Tomita Y
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359359
[TBL] [Abstract][Full Text] [Related]
20. Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy.
Drobner J; Portal D; Runcie K; Yang Y; Singer EA
J Kidney Cancer VHL; 2023; 10(3):37-60. PubMed ID: 37789902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
